Biden’s Prostate Cancer Diagnosis Highlights Flaws in Screening Guidelines

Biden’s Prostate Cancer Diagnosis Highlights Flaws in Screening Guidelines

The COVID pandemic has underscored significant gaps in healthcare protocols, especially regarding flexibility and accuracy in medical guidelines. As a practicing internist with years of experience, my approach has never solely relied on rigid guidelines; rather, I use them as a framework for personalized treatment. Medicine is an art, requiring individualized care tailored to each patient.

One troubling guideline is the U.S. Preventive Services Task Force recommendation, in place since 2012, which advises against routine Prostate-Specific Antigen (PSA) testing for prostate cancer screening. Additionally, the American Urological Association no longer supports routine PSA screening for men over 70 years old. This decline in screening rates among men aged 40 and older is alarming, particularly given that there are over 300,000 new cases of prostate cancer diagnosed annually in the U.S., resulting in over 35,000 deaths each year, many of which could potentially be prevented through early detection.

If recent statements from former President Biden’s spokesperson are accurate, it appears that he went without a prostate cancer screening for over a decade leading up to his alarming diagnosis of aggressive metastatic disease. This situation raises critical questions. Were Biden and his healthcare providers strictly adhering to outdated guidelines? Or is this a case of concealing a more timely diagnosis from the public, similar to other health concerns regarding the former president?

Biden’s Last Known Prostate Cancer Screening Occurred Over a Decade Ago, Question Marks Arise Around Diagnosis

Medicine should not involve delay and uncertainty, a sentiment shared by many internists and urologists. An increase in PSA levels often signals that something is amiss in the prostate. Rising PSA levels, particularly beyond a threshold of 4, warrant closer examination. While elevated levels may not always indicate prostate cancer, a low reading in conjunction with